[go: up one dir, main page]

MX2019007389A - Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno. - Google Patents

Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.

Info

Publication number
MX2019007389A
MX2019007389A MX2019007389A MX2019007389A MX2019007389A MX 2019007389 A MX2019007389 A MX 2019007389A MX 2019007389 A MX2019007389 A MX 2019007389A MX 2019007389 A MX2019007389 A MX 2019007389A MX 2019007389 A MX2019007389 A MX 2019007389A
Authority
MX
Mexico
Prior art keywords
asenapine
therapeutic system
transdermal therapeutic
polyisobutylene
polysiloxane
Prior art date
Application number
MX2019007389A
Other languages
English (en)
Other versions
MX382132B (es
Inventor
Mohr Patrick
Rietscher René
Eifler René
Bourquain Olga
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2019007389A publication Critical patent/MX2019007389A/es
Publication of MX382132B publication Critical patent/MX382132B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a un sistema terapeutico transdermico (STT) para la administracion transdermica de asenapina que comprende una estructura de capas autoadhesivas que comprende una cantidad terapeuticamente eficaz de asenapina, dicha estructura de capas autoadhesiva comprende: A) una capa de refuerzo; B) una capa que contiene asenapina que comprende: 1. asenapina en forma de base libre; y 2. un polimero seleccionado del grupo que consiste en polisiloxanos y poliisobutilenos en una cantidad de mas de 50% en peso con base en el peso total de la capa que contiene asenapina; y C) opcionalmente una capa adicional de contacto con la piel.
MX2019007389A 2016-12-20 2017-12-19 Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno MX382132B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16205502 2016-12-20
EP17178268 2017-06-28
PCT/EP2017/083640 WO2018115010A1 (en) 2016-12-20 2017-12-19 Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene

Publications (2)

Publication Number Publication Date
MX2019007389A true MX2019007389A (es) 2019-08-16
MX382132B MX382132B (es) 2025-03-13

Family

ID=60915504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007389A MX382132B (es) 2016-12-20 2017-12-19 Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno

Country Status (11)

Country Link
US (2) US11337932B2 (es)
EP (1) EP3558276B1 (es)
JP (1) JP7149287B2 (es)
KR (1) KR102614709B1 (es)
CN (1) CN110087641B (es)
AU (1) AU2017384392B2 (es)
CA (1) CA3047354A1 (es)
ES (1) ES3001152T3 (es)
MX (1) MX382132B (es)
RU (1) RU2764443C2 (es)
WO (1) WO2018115010A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382195B (es) 2016-12-20 2025-03-13 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
PL3810100T3 (pl) * 2018-06-20 2025-05-12 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP7274834B2 (ja) * 2018-08-10 2023-05-17 久光製薬株式会社 アセナピン含有貼付剤
EP3861999A4 (en) * 2018-10-01 2022-06-22 Hisamitsu Pharmaceutical Co., Inc. ADHESIVE PAD CONTAINING ASENAPINE
CN112789039B (zh) * 2018-10-01 2023-10-24 久光制药株式会社 含有阿塞那平的贴剂
AU2020370073A1 (en) * 2019-10-22 2022-05-12 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
EP4052703A4 (en) * 2019-10-28 2023-12-20 Hisamitsu Pharmaceutical Co., Inc. METHOD FOR SUPPRESSING THE PRODUCTION OF ASENAPINE N-OXIDE
DE102020207642A1 (de) * 2020-06-19 2021-12-23 Lts Lohmann Therapie-Systeme Ag Verfahren zur herstellung von asenapin in form seiner freien base
EP4226921A4 (en) * 2020-11-16 2024-11-13 Hisamitsu Pharmaceutical Co., Inc. TRANSDERMAL PATCH CONTAINING ASENAPINE

Family Cites Families (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158059A (en) 1976-05-24 1979-06-12 Akzona Incorporated Tension reducing 2,3,4,4a,9,136-hexahydro-dibenz[1,2;5,6]cyclohepta[3,4-c]py
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
AU576884B2 (en) 1984-07-23 1988-09-08 Schering Corporation Transdermal delivery of azatadine
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
EP0387751B1 (en) 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
EP0569096A1 (en) 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
CN1079670C (zh) 1994-03-02 2002-02-27 阿克佐诺贝尔公司 舌下或颊给药的药物组合物
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
TR199902727T2 (xx) 1997-05-26 2000-07-21 Akzo Nobel N.V. Aromatik s�lfonik asitlerin tuzlar�.
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
GB9714650D0 (en) 1997-07-11 1997-09-17 Strakan Ltd Block copolymer
AU2418499A (en) 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
DE19814083C2 (de) 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
KR20010071049A (ko) 1998-07-29 2001-07-28 야스이 쇼사꾸 점착성 조성물 및, 각각 당해 조성물을 함유하는 투습성점착 테이프, 점착성 약제 조성물 및 점착 테이프 제제
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
US20040142024A1 (en) 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
MXPA03003957A (es) 2000-11-06 2003-08-19 Samyang Corp Sistema de liberacion transdermica de farmacos, con propiedades mejoradas de adhesion y absorbencia de agua.
NZ526801A (en) 2001-01-02 2005-07-29 Upjohn Co Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
EP1366762B1 (en) 2001-03-07 2015-12-30 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
EP1404342A1 (en) 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
JP2006505489A (ja) 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
JP4323138B2 (ja) 2002-06-05 2009-09-02 日東電工株式会社 経皮吸収型製剤およびその製造方法
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
ATE423560T1 (de) 2002-08-20 2009-03-15 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
AU2003268376A1 (en) 2002-08-30 2004-11-26 Watson Pharmaceuticals, Inc. Transdermal delivery systems and methods
AU2003284899A1 (en) 2002-10-29 2004-05-25 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
GB0302662D0 (en) 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
GB0306604D0 (en) 2003-03-21 2003-04-30 Curidium Ltd Second medical use
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
TWI327915B (en) 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
CN1874740A (zh) 2003-10-10 2006-12-06 奥来克西公司 经皮高分子量和低分子量化合物
RU2356580C2 (ru) 2003-10-28 2009-05-27 Новен Фармасьютикалз, Инк Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств
CA2546200A1 (en) 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
EP1576985A1 (en) 2004-03-18 2005-09-21 B&B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
JP2007519705A (ja) 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
BRPI0507609A (pt) 2004-02-13 2007-07-03 Pfizer Prod Inc combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
US7650848B2 (en) 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
CA2556380A1 (en) 2004-03-02 2005-09-15 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
JP4961207B2 (ja) 2004-04-21 2012-06-27 久光製薬株式会社 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤
BRPI0510074A (pt) 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
CA2565996A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
EP1765310B1 (en) 2004-05-28 2015-10-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
WO2006000222A2 (en) 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
US20060019969A1 (en) 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of allodynia
ITMI20041628A1 (it) 2004-08-06 2004-11-06 Bouty S P A Sistema terapeutico a rilascio controllato per uso topico transdermico
GB0417702D0 (en) 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
US20060039869A1 (en) 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs
US20060078602A1 (en) 2004-10-08 2006-04-13 Noven Pharmaceuticals, Inc. Device for transdermal administration of drugs including acrylic polymers
TW200628175A (en) 2004-10-08 2006-08-16 Noven Pharma Transdermal drug delivert device including an occlusive backing
MX2007004485A (es) 2004-10-15 2007-06-13 Organon Nv Tratamiento de desordenes bipolares y sintomas asociados.
DE602005010812D1 (de) 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
US20060150989A1 (en) 2005-01-12 2006-07-13 Peter Migaly Method of diagnosing, treating and educating individuals with and/or about depression
AR057643A1 (es) 2005-01-28 2007-12-12 Sanol Arznei Schwarz Gmbh Lacosamida para terapia adjunta
WO2006082728A1 (ja) 2005-02-04 2006-08-10 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収貼付剤
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
PT1917267E (pt) 2005-04-07 2009-02-04 Organon Nv Forma cristalina de maleato de asenapina
BRPI0610677A2 (pt) 2005-04-07 2012-10-30 Organon Nv derivado de trans-aminoácido, e, processos para a preparação do mesmo e para a preparação de asenapina
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
CA2607524A1 (en) 2005-04-27 2006-11-09 Umn Pharma Inc. Agent for prophylaxis and treating of pancreatitis
DE602006003813D1 (de) 2005-06-06 2009-01-08 Fujimoto Co Ltd Pharmazeutische Zusammensetzung zur perkutane Absorption unter Verwendung von einem Metalchlorid, vorzugsweise Natriumchlorid, zur Vorbeugung von Kohäsionsschwäche
CA2548864C (en) 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
JP5000932B2 (ja) 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
US20070015763A1 (en) 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
TW200738734A (en) 2005-08-08 2007-10-16 Pfizer Prod Inc Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
WO2007046554A1 (ja) 2005-10-21 2007-04-26 Sumitomo Chemical Company, Limited ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP5037831B2 (ja) 2006-02-15 2012-10-03 久光製薬株式会社 凝集力向上及び徐放化の外用貼付剤
MX2008012486A (es) 2006-03-27 2008-10-10 Panacea Biotec Ltd Composicion farmaceutica de liberacion sostenida basada en un sistema de liberacion que comprende un polimero soluble en acido y un polimero independiente del ph.
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20070259952A1 (en) 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
WO2007137224A2 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
WO2007145996A2 (en) 2006-06-06 2007-12-21 Dow Corning Corporation A silicone acrylate hybrid composition
RU2445959C2 (ru) 2006-06-09 2012-03-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новый лейкопластырный препарат
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
TW200817414A (en) 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
CN101506172A (zh) 2006-07-14 2009-08-12 辉瑞产品公司 （7S）-7-[（5-氟-2-甲基-苄基）氧基]-2-[（2R）-2-甲基哌嗪-1-基]-6，7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080090892A1 (en) 2006-10-06 2008-04-17 N.V. Organon Amorphous asenapine and processes for preparing same
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
CA2671081C (en) 2006-12-01 2014-06-03 Nitto Denko Corporation Stabilized adhesive preparation containing donepezil
US20100048628A1 (en) 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
CN101563312A (zh) 2006-12-22 2009-10-21 住友化学株式会社 阿塞那平合成中间体的制备方法
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
KR101460820B1 (ko) 2007-01-16 2014-11-11 아이피아이엔티엘, 엘엘씨 대사 증후군의 치료를 위한 신규한 조성물
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
WO2008141438A1 (en) 2007-05-17 2008-11-27 Sunnybrook Health Sciences Centre Gabaergic modulators for treating airway conditions
EP2170399A1 (en) 2007-06-05 2010-04-07 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
WO2009000890A2 (en) 2007-06-27 2008-12-31 N.V. Organon Medication container
JP5245428B2 (ja) 2007-07-06 2013-07-24 住友化学株式会社 トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
JP5224163B2 (ja) 2007-07-24 2013-07-03 コスメディ製薬株式会社 経皮吸収テープ製剤
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
US20110269777A1 (en) 2007-08-01 2011-11-03 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
JP2011507800A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
WO2009087058A1 (en) 2008-01-04 2009-07-16 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US8529441B2 (en) 2008-02-12 2013-09-10 Innurvation, Inc. Ingestible endoscopic optical scanning device
BRPI0907570A2 (pt) 2008-02-13 2019-09-24 Targacept Inc agonistas alfa7 nicotínico e antipsicóticos
WO2009107477A1 (ja) 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
JP5301190B2 (ja) 2008-03-31 2013-09-25 積水メディカル株式会社 貼付剤
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20110182949A1 (en) 2008-05-30 2011-07-28 Jiashang Tang Stabilized transdermal drug delivery system
NZ588311A (en) 2008-07-24 2012-08-31 Handa Pharmaceuticals Llc Stabilized atypical antipsychotic formulation to treat psychiatric conditions
US9267151B2 (en) 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
WO2010026154A1 (en) 2008-09-04 2010-03-11 Neurosearch A/S A method for combating adverse effects arising from antipsychotic treatment
WO2010060742A1 (en) 2008-11-03 2010-06-03 Solvay Pharmaceuticals B.V. Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
WO2010073326A1 (ja) 2008-12-24 2010-07-01 ニチバン株式会社 経皮吸収型製剤
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CA3037010A1 (en) 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
EP2405967B1 (en) 2009-03-12 2020-09-23 Delpor, Inc. Implantable device for long-term delivery of drugs
CN102612381B (zh) 2009-03-20 2015-09-09 安塔瑞斯制药公司 危险试剂注入系统
WO2010110914A2 (en) 2009-03-27 2010-09-30 Zirus, Inc. Mammalian genes involved in infection
EP2236157A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Pipamperone and a second agent in treating mood and anxiety disorders
EP2413935A1 (en) 2009-03-30 2012-02-08 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood disorders
EP2236138A1 (en) 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
WO2010119455A2 (en) 2009-04-15 2010-10-21 Sun Pharma Advanced Research Company Ltd. An injectable sustained release pharmaceutical composition
WO2010121358A1 (en) 2009-04-21 2010-10-28 Sanomune Inc. Tissue kallikrein for the treatment of schizophrenia and bipolar disorder
BRPI1014886B1 (pt) 2009-04-24 2020-02-11 Henkel IP & Holding GmbH Polímeros acrílicos de silicone híbridos, seus métodos de preparação, adesivos e soluções de uma composição adesiva sensível à pressão compreendendo os mesmos.
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
TWI552773B (zh) 2009-05-01 2016-10-11 久光製藥股份有限公司 經皮吸收型製劑
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
AR077225A1 (es) 2009-06-24 2011-08-10 Organon Nv Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
US20110306596A1 (en) 2009-07-27 2011-12-15 Auspex Pharmaceuticals, Inc. Benzazepine inhibitors of gamma-secretase
AR077429A1 (es) 2009-07-29 2011-08-24 Organon Nv Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
AU2010286450A1 (en) 2009-08-31 2012-04-12 Eric B. Schneider Treatment and prevention of secondary injury after trauma or damage to the central nervous system
WO2011047341A2 (en) 2009-10-16 2011-04-21 University Of South Florida Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
CA2784826A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
US8202525B2 (en) 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
ES2647361T3 (es) 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
US20110166194A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Asenapine Prodrugs
WO2011085188A1 (en) 2010-01-07 2011-07-14 Eurand, Inc. Pharmaceutical compositions comprising anti-psychotic drugs
ITMI20100260A1 (it) 2010-02-19 2011-08-20 Giulio Scigliano Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici
JP5615898B2 (ja) 2010-02-24 2014-10-29 久光製薬株式会社 貼付剤
JP5615899B2 (ja) 2010-02-24 2014-10-29 久光製薬株式会社 経皮吸収製剤
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
WO2011136283A1 (ja) 2010-04-28 2011-11-03 久光製薬株式会社 皮膚刺激抑制剤及び経皮吸収製剤
WO2011143755A1 (en) 2010-05-21 2011-11-24 Serdar Dursun Compositions and methods of treating schizophrenia
CN101851242B (zh) 2010-05-25 2013-07-24 上海皓元生物医药科技有限公司 阿塞那平中间体的制备方法
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
KR101810717B1 (ko) 2010-07-29 2017-12-19 라보라토리오스 레스비, 에스.엘. 아세나핀을 제조하는 신규한 방법
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
WO2012038975A2 (en) 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
WO2012040845A1 (en) 2010-09-27 2012-04-05 Alphora Research Inc. Process for the preparation of tetracyclic derivatives and intermediate products used in the process
EP2638005A4 (en) 2010-11-12 2015-04-01 Promentis Pharm Inc S-T-BUTYL-CYSTONE-PROTECTED DI-PEPTIDE ANALOGS AND ASSOCIATED COMPOUNDS
US20120122793A1 (en) 2010-11-12 2012-05-17 Promentis Pharmaceuticals, Inc. S-Protected Cysteine Analogs and Related Compounds
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
BR112013012156A2 (pt) 2010-11-17 2017-12-05 Hexal Ag sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
WO2012070043A1 (en) 2010-11-26 2012-05-31 Ramot At Tel-Aviv University Ltd. Method and composition for weight-gain management
EP2667857A4 (en) 2010-11-26 2015-11-25 Univ Witwatersrand Jhb ACTIVE RELEASE DEVICE
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
NZ612187A (en) 2010-12-23 2015-07-31 Alkermes Pharma Ireland Ltd Multi-api loading prodrugs
EP2468751B1 (en) 2010-12-24 2016-03-16 Medichem, S.A. Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012114325A1 (en) 2011-02-23 2012-08-30 Mapi Pharma Limited Polymorphs of asenapine maleate
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
JP5698837B2 (ja) 2011-04-18 2015-04-08 久光製薬株式会社 貼付剤の製造方法及び貼付剤
CN102229613B (zh) 2011-04-27 2013-08-07 上海华升生物科技有限公司 阿森纳平的合成工艺
ITMI20110734A1 (it) 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
JP6014656B2 (ja) 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
EP2727473A4 (en) 2011-06-28 2015-05-06 Vivozon Inc COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
SG195200A1 (en) 2011-06-29 2013-12-30 Otsuka Pharma Co Ltd Quinazolines as therapeutic compounds and related methods of use
WO2013024492A2 (en) 2011-07-01 2013-02-21 Megafine Pharma (P) Ltd. A process for the preparation of asenapine and novel salts thereof
CA2840983C (en) 2011-07-07 2016-09-27 Teikoku Seiyaku Co., Ltd. Adhesive skin patch containing serotonin receptor antagonist drug
WO2013011461A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of asenapine maleate
US9457014B2 (en) 2011-07-28 2016-10-04 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
AR082640A1 (es) 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
CN102952144A (zh) 2011-08-29 2013-03-06 上海华拓医药科技发展股份有限公司 阿森纳平马来酸盐的晶型、制备方法及其药物组合物
WO2013035109A1 (en) 2011-09-08 2013-03-14 Mylan Laboratories Ltd Improved process for the preparation of asenapine maleate
WO2013040419A1 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
WO2013061247A1 (en) 2011-10-24 2013-05-02 Alembic Pharmaceuticals Limited Novel process for the preparation of asenapine
EP2770981B1 (en) 2011-10-24 2017-05-24 Braeburn Pharmaceuticals, Inc. Implantable tizanidine compositions and methods of treatment thereof
WO2013067519A2 (en) 2011-11-04 2013-05-10 Purdue Research Foundation Insect and tick g-coupled receptors useful as targets for insecticides and compounds and reagents identified using the same
US20140336391A1 (en) 2011-11-28 2014-11-13 Ranbaxy Laboratories Limited Process for the preparation of asenapine intermediate
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN103183680A (zh) 2011-12-27 2013-07-03 上海华拓医药科技发展股份有限公司 阿森那平的制备方法
WO2013114400A2 (en) 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
CN103254201B (zh) 2012-02-21 2016-04-13 四川科伦药物研究有限公司 一种阿塞那平的制备方法
ES2637341T3 (es) 2012-03-14 2017-10-11 Levicept Ltd. Proteína de unión a neurotrofina P75NTR para su utilización terapéutica
DE102012205493A1 (de) 2012-04-03 2013-10-10 Acino Ag Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem
CN104350142A (zh) 2012-04-18 2015-02-11 海莫希尔有限责任公司 病理或生理性病况的体外模型
KR20130120648A (ko) 2012-04-26 2013-11-05 에스에프씨 주식회사 벤조사이클로플루오렌계 화합물 및 이를 포함하는 유기전계발광소자
CN102657635B (zh) 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
US20150141274A1 (en) 2012-05-09 2015-05-21 The Rockefeller University Methods and Compositions for Activity Dependent Transcriptome Profiling
CN102746209A (zh) 2012-06-20 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种3-（2-（4-氯苯氧基）苯基）-1-甲基-2,4-二酮的合成方法
WO2013190481A1 (en) 2012-06-21 2013-12-27 Alembic Pharmaceuticals Limited Process for preparing asenapine and salts of intermediates thereof
CN104487071B (zh) 2012-07-26 2017-06-13 久光制药株式会社 贴附剂
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
JP6538559B2 (ja) 2012-09-28 2019-07-03 デルポー，インコーポレイティド 抗精神病薬の徐放のための装置及び方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
JOP20210047A1 (ar) 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014078377A1 (en) 2012-11-14 2014-05-22 Agenebio, Inc. Methods and compositions for treating schizophrenia
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN102976998A (zh) 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种3 -（5-氯-2-苯氧基-苯基）-1-甲基-吡咯烷-2,4-二酮的合成方法
CN104812394B (zh) 2012-11-26 2018-10-19 开普敦大学 吩噻嗪衍生物及其治疗肺结核的用途
CN102976929A (zh) 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种（4-氯-2-苯氧基苯基）乙酸的合成方法
JP2014105205A (ja) 2012-11-30 2014-06-09 Medical Front Co Ltd 医用貼付剤
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
EP2938608B1 (en) 2012-12-20 2021-08-04 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
CN103893139B (zh) 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
JP6359032B2 (ja) 2012-12-28 2018-07-18 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮薬物送達用のマルチポリマー組成物
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
CN103120688A (zh) 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
CN103965206A (zh) 2013-01-29 2014-08-06 北京京卫燕康药物研究所有限公司 一种阿色纳品马来酸盐的新晶型及制备方法
CN103099799B (zh) 2013-02-06 2014-08-06 上海现代药物制剂工程研究中心有限公司 复合膜状制剂及其制备方法
CN103083284B (zh) 2013-02-06 2014-08-06 上海现代药物制剂工程研究中心有限公司 膜状制剂及其制备方法
WO2014121332A1 (en) 2013-02-06 2014-08-14 Sillender Mark Therapeutic substance transfer catheter and method
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
CN103113379A (zh) 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2014160026A2 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
WO2014160167A1 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising aromatic polyurethanes and methods of treatment thereof
US20140276479A1 (en) 2013-03-14 2014-09-18 Noven Pharmaceuticals, Inc. Transdermal drug delivery system with overlay
WO2014152965A2 (en) 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
WO2014160155A2 (en) 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
EP2968248A4 (en) 2013-03-15 2016-08-31 Nal Pharmaceutical Group Ltd TRANSDERMAL ACTIVE COMPOSITION SYSTEM WITH RIVASTIGMIN
WO2014145680A1 (en) 2013-03-15 2014-09-18 Ameritox, Ltd. Methods of normalizing measured drug concentrations and testing for potential non-compliance with a drug treatment regimen
AR095259A1 (es) 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
BR112015023922A2 (pt) 2013-03-15 2017-07-18 Als Mountain Llc composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
JP6129632B2 (ja) 2013-04-24 2017-05-17 帝國製薬株式会社 貼付剤
CN103254202A (zh) 2013-05-19 2013-08-21 甘肃皓天化学科技有限公司 阿塞纳平的制备方法
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014207664A2 (en) 2013-06-28 2014-12-31 Alembic Pharmaceuticals Limited Stable pharmaceutical composition of asenapine
CN103342707B (zh) 2013-06-28 2015-09-02 甘肃皓天化学科技有限公司 用于制备阿塞纳平中间体的制备方法
CN103351393B (zh) 2013-07-03 2016-04-06 华裕(无锡)制药有限公司 用于制备阿森那平之还原剂及阿森那平之制备方法
WO2015027342A1 (en) 2013-08-30 2015-03-05 Mcmaster University Microgel compositions for delivery of substances to the brain
CN104447771A (zh) 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 一种稳定的马来酸阿塞那平化合物
CN104447770A (zh) 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 阿塞那平化合物
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
IN2013MU03596A (es) 2013-11-18 2015-07-24 Piramal Entpr Ltd
PL3076967T3 (pl) 2013-12-03 2021-12-20 Intra-Cellular Therapies, Inc. Metody leczenia objawów rezydualnych schizofrenii
WO2015082562A1 (en) 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
WO2015087926A1 (ja) 2013-12-12 2015-06-18 久光製薬株式会社 積層型貼付剤
CN103772400A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
CN103772402A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 一种新的阿塞那平马来酸盐粗品精制方法
CN103772401A (zh) 2014-01-07 2014-05-07 万特制药(海南)有限公司 11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
CN103760258A (zh) 2014-01-07 2014-04-30 万特制药(海南)有限公司 一种用液相色谱法分离测定马来酸阿塞那平有关物质的方法
CN103760280A (zh) 2014-01-10 2014-04-30 万特制药(海南)有限公司 一种用液相色谱法分离测定阿塞那平中间体有关物质的方法
RU2757221C2 (ru) 2014-02-07 2021-10-12 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
WO2015125152A2 (en) 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
US20170189443A1 (en) 2014-02-24 2017-07-06 C. Lowell Parsons Compositions and methods for treatment of diseases and conditions employing oral administration of sodium pentosan polysulfate and other pentosan polysulfate salts
SG11201607137WA (en) 2014-02-28 2016-09-29 Camh Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain
WO2015127558A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating micturition in a patient in need thereof
WO2015127556A1 (en) 2014-02-28 2015-09-03 UNIVERSITé LAVAL Methods and uses for inducing or facilitating defecation in a patient in need thereof
CN103864802B (zh) 2014-03-31 2016-08-17 四川科伦药业股份有限公司 马来酸阿塞那平的制备方法
CN104974168B (zh) 2014-04-02 2019-01-04 洋浦慧谷医药有限公司 阿塞那平的制备方法以及用于制备阿塞那平的中间体
CN104974167B (zh) 2014-04-02 2019-01-04 洋浦慧谷医药有限公司 阿塞那平的制备方法以及用于制备阿塞那平的中间体
EP3125892A4 (en) 2014-04-04 2017-12-27 Intra-Cellular Therapies, Inc. Organic compounds
MX388258B (es) 2014-04-04 2025-03-19 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
CN104000800A (zh) 2014-04-28 2014-08-27 万特制药(海南)有限公司 马来酸阿塞那平口腔速溶膜剂及其制备方法
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
EP3643355A1 (en) 2014-06-03 2020-04-29 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CN104133010B (zh) 2014-07-01 2019-11-29 北京万全德众医药生物技术有限公司 高效液相色谱法分离分析阿西马朵林中间体及光学异构体
CN104133012B (zh) 2014-07-02 2020-01-07 北京万全德众医药生物技术有限公司 一种高效液相色谱法测定马来酸阿塞那平消旋体的方法
EP3169318B1 (en) 2014-07-18 2020-04-01 Buzzz Pharmaceuticals Limited Abuse deterrent opiod/opiod-antagonist transdermal patch
CN104098580B (zh) 2014-07-22 2016-04-13 成都百裕科技制药有限公司 一种阿塞那平关键中间体的制备方法
ES2733812T3 (es) 2014-07-31 2019-12-03 Noven Pharma Polímeros acrílicos que contienen silicona para composiciones de administración transdérmica de fármacos
ES2562684B1 (es) 2014-08-04 2017-02-06 Consejo Superior De Investigaciones Científicas (Csic) Método de monitorización de tratamiento antipsicótico
US20170231957A1 (en) 2014-08-14 2017-08-17 Alrise Biosystems Gmbh Injectable formulations of asenapine
JP2016056142A (ja) 2014-09-11 2016-04-21 第一三共株式会社 Ｐｄｅ１０ａ阻害薬と抗精神病薬の組み合わせ
CN104297366A (zh) 2014-09-24 2015-01-21 万特制药(海南)有限公司 马来酸阿塞那平及其杂质的液相分析方法
EA201790693A1 (ru) 2014-10-14 2017-09-29 Скюлпт Б.В. Коррекция фигуры
TW201615219A (zh) 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 呼吸系統疾病用藥臨床新應用
EP3020782B1 (en) 2014-11-11 2018-08-01 SFC Co., Ltd. An electroluminescent compound and an electroluminescent device comprising the same
CA2965157A1 (en) 2014-11-25 2016-06-02 Nanocopoeia, Llc Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
WO2016089737A1 (en) 2014-12-01 2016-06-09 The Feinstein Institute For Medical Research Use of striatal connectivity patterns for evaluating antipsychotic agents
CA2969142A1 (en) 2014-12-05 2016-06-09 Myriad Genetics, Inc. Biomarkers for distinguishing mood disorders
EP3031458A1 (en) 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
WO2016114655A1 (en) 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2016121805A1 (ja) 2015-01-30 2016-08-04 積水メディカル株式会社 貼付剤
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
WO2016138138A1 (en) 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
WO2016140087A1 (ja) 2015-03-02 2016-09-09 久光製薬株式会社 貼付剤
KR20160107610A (ko) 2015-03-04 2016-09-19 한국과학기술원 대사 질환의 예방 또는 치료용 조성물
ITUB20150635A1 (it) 2015-04-14 2016-10-14 Giuseppe Lotito Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
EP3285753A1 (en) 2015-04-22 2018-02-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
US20190055603A1 (en) 2015-04-28 2019-02-21 Proove Biosciences, Inc. System and method for processing genotype information relating to drug metabolism
WO2016209982A1 (en) 2015-06-22 2016-12-29 Corium International, Inc. Transdermal adhesive composition comprising a poorly soluble therapeutic agent
ES2598248B1 (es) 2015-06-26 2017-12-18 Centro De Investigación Biomédica En Red Método in vitro y kit para el pronóstico o predicción de la respuesta al tratamiento con agentes antipsicóticos por parte de pacientes que han sufrido un primer episodio psicótico
CN107847488A (zh) 2015-07-27 2018-03-27 久光制药株式会社 含有阿塞那平的贴剂的制造方法
US10806705B2 (en) * 2015-07-27 2020-10-20 Hisamitsu Pharmaceutical Co., Inc. Asenapine-containing patch
CN105566336A (zh) 2016-01-08 2016-05-11 万特制药(海南)有限公司 一种制备阿塞那平去甲基杂质的新方法
CN105693735A (zh) 2016-01-15 2016-06-22 万特制药(海南)有限公司 马来酸阿塞那平一种制备方法
WO2017131034A1 (ja) 2016-01-28 2017-08-03 久光製薬株式会社 経皮吸収製剤
JP6658201B2 (ja) 2016-03-28 2020-03-04 東洋インキＳｃホールディングス株式会社 貼付剤
KR20160108258A (ko) 2016-06-20 2016-09-19 한국과학기술원 대사 질환의 예방 또는 치료용 조성물
US20180008612A1 (en) 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
AU2017302305A1 (en) 2016-07-27 2019-02-14 Corium, LLC. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
WO2018081812A2 (en) 2016-10-31 2018-05-03 Teikoku Pharma Usa, Inc. Methods of managing pain using dexmedetomidine transdermal delivery devices
MX382195B (es) 2016-12-20 2025-03-13 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
PL3810100T3 (pl) 2018-06-20 2025-05-12 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN112830931A (zh) 2019-08-13 2021-05-25 浙江奥翔药业股份有限公司 制备阿塞那平的方法
DE102020207642A1 (de) 2020-06-19 2021-12-23 Lts Lohmann Therapie-Systeme Ag Verfahren zur herstellung von asenapin in form seiner freien base

Also Published As

Publication number Publication date
WO2018115010A1 (en) 2018-06-28
US12485099B2 (en) 2025-12-02
AU2017384392A1 (en) 2019-08-08
RU2019119938A (ru) 2021-01-22
MX382132B (es) 2025-03-13
RU2764443C2 (ru) 2022-01-17
EP3558276B1 (en) 2024-11-06
CA3047354A1 (en) 2018-06-28
ES3001152T3 (es) 2025-03-04
KR102614709B1 (ko) 2023-12-18
BR112019012573A2 (pt) 2019-11-19
EP3558276A1 (en) 2019-10-30
JP7149287B2 (ja) 2022-10-06
US20220323370A1 (en) 2022-10-13
CN110087641B (zh) 2024-03-12
EP3558276C0 (en) 2024-11-06
RU2019119938A3 (es) 2021-03-02
CN110087641A (zh) 2019-08-02
US20200085759A1 (en) 2020-03-19
KR20190099230A (ko) 2019-08-26
JP2020511523A (ja) 2020-04-16
US11337932B2 (en) 2022-05-24
AU2017384392B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
PE20160002A1 (es) Sistema de liberacion transdermico
CR20150360A (es) Sistema de liberación transdérmica
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
AR101358A1 (es) Composiciones de polímeros acrílicos que contienen siliconas para la administración transdérmica de fármacos
UY37594A (es) Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
MX382471B (es) Parche de microagujas para administrar un ingrediente activo a la piel.
MX2019001103A (es) Sistema de suministro transdermico de donepezilo.
AR081539A1 (es) Composicion a base de fexofenadina y procedimiento de preparacion, sobre o comprimido, uso de la composicion
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
PH12015502280A1 (en) Transdermal delivery system comprising donepezil or its salt
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
BR112017002796A2 (pt) método de induzir saciedade
UA114101C2 (xx) Трансдермальна терапевтична система для введення фентанілу або його аналога
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
BR112019007325A2 (pt) sistema terapêutico tópico de duas camadas
PE20200863A1 (es) Preparacion de absorcion percutanea que comprende donepezilo, monocaprilato de propilenglicol y copolimero de bloque de estireno-isopreno-estireno para la prevencion de la demencia causada por alzheimer
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
MX2020004250A (es) Composicion farmaceutica de liberacion sostenida.